A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2014
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms GEMSO
- 04 Aug 2012 Additional lead trial center identified as reported by European Clinical Trials Database.
- 16 Nov 2011 Actual end date (20 Jul 2011) added as reported by European Clinical Trials Database.
- 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.